BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 8489751)

  • 1. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.
    Chi IC
    Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
    Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
    Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.
    Sivin I; el Mahgoub S; McCarthy T; Mishell DR; Shoupe D; Alvarez F; Brache V; Jimenez E; Diaz J; Faundes A
    Contraception; 1990 Oct; 42(4):361-78. PubMed ID: 2124179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T.
    Andersson K; Batar I; Rybo G
    Contraception; 1992 Dec; 46(6):575-84. PubMed ID: 1493717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial.
    Andersson K; Odlind V; Rybo G
    Contraception; 1994 Jan; 49(1):56-72. PubMed ID: 8137626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five years' experience with levonorgestrel-releasing IUDs.
    Luukkainen T; Allonen H; Haukkamaa M; Lähteenmäki P; Nilsson CG; Toivonen J
    Contraception; 1986 Feb; 33(2):139-48. PubMed ID: 3084167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levonorgestrel IUD].
    Skajaa K; Forman A
    Ugeskr Laeger; 1994 Nov; 156(46):6884-7. PubMed ID: 7839510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ.
    Gu Z; Zhu P; Luo H; Zhu X; Zhang G; Wu S
    Contraception; 1995 Jul; 52(1):57-61. PubMed ID: 8521716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
    Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.
    Nilsson CG; Allonen H; Diaz J; Luukkainen T
    Fertil Steril; 1983 Feb; 39(2):187-92. PubMed ID: 6401636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
    Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.